Staff Case Management Team - Case Management, Japan Drug Safety Unit
About the job
- Proficiency with personal computers.
- Fluent Japanese, including the ability to understand and explain Japanese regulations and prepare regulatory documents in Japanese.
- A medical-related qualification, such as registered pharmacist, or a science background at college level or above.
- Ability to identify and practically resolve day-to-day work challenges.
- Ability to make decisions with a clear view of their expected outcomes.
- Ability to meet departmental work-quality standards while achieving personal goals.
- Ability to work as part of a team.
- English speaking and writing skills, with a TOEIC score above 600.
- Collect and assess adverse-event safety information for marketed products and investigational Pfizer products.
- Enter and manage data in the global safety database.
- Comply with Japanese, U.S., and European laws and regulations and maintain safety compliance.
- Contribute to domestic and international internal audits and regulatory inspections.
- Respond to inquiries regarding Individual Case Safety Reports.
- Participate in projects related to developing global safety processes.
- Experience in pharmacovigilance and/or safety data management.
- Experience or skills in medical writing.
- Experience relating to safety databases.
- English speaking and writing skills with a TOEIC score above 730.
About the company
Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Get referred to Pfizer
See people who can refer or advise you
Simplify's Take
What believers are saying
- Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
- The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
- Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.
What critics are saying
- Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
- Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
- Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.
What makes Pfizer unique
- Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
- Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
- Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
-4%1 year growth
-3%2 year growth
-3%Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.
High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.
Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.
The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.
Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.